NORTH PALM BEACH, Fla., Feb. 20, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced that on February 18, 2026, it received a public warning letter (the “Letter”) from the NYSE Regulation Staff of the New York Stock Exchange (the “Exchange”) notifying the Company that it failed to comply with Sections 301 and 713 of the NYSE American LLC Company Guide (the “Company Guide”). The Letter relates to the issuance of approximately 7.5 million shares (the “Subj ...

Ramsay Health Care Update Summary Company Overview - **Company**: Ramsay Health Care (OTCPK:RMYH.Y) - **Date of Briefing**: February 19, 2026 Key Points Strategic Review and Share Distribution - Ramsay Health Care announced the outcome of a comprehensive strategic review regarding its 52.79% shareholding in Ramsay Santé, proposing an in-specie distribution of Ramsay Santé shares to Ramsay shareholders to simplify the group and enhance focus on distinct strategic priorities [1][2] - The distribution aims to support Ramsay Health Care's transformation and growth potential in its core Australian hospital business [1] Rationale for the Proposal - Ramsay and Ramsay Santé operate in different geographic markets with distinct capital profiles and strategic objectives, allowing each business to focus on its respective strategies [2] - The proposal is expected to simplify Ramsay's financial profile by deconsolidating Ramsay Santé from its financial statements, providing shareholders the option to retain ownership in Ramsay Santé [2] Implementation Timeline - The in-specie distribution is expected to be completed in the fourth quarter of calendar 2026, subject to necessary approvals [3] - A demerger booklet will be distributed ahead of a shareholder vote in Q4 2026, containing all relevant information [4] Termination of Shareholder Agreement - Ramsay Health Care has given notice to terminate the existing shareholders' agreement with Predica, which will be effective from October 1, 2026 [3][15] - The termination is aligned with Ramsay's strategic shift towards Europe and its shareholding in Ramsay Santé [15] Financial and Operational Considerations - The management does not anticipate significant operational synergies or material dyssynergies post-demerger, focusing instead on the transformation of the Australian business [11][21] - The separation process is expected to be relatively simple due to Ramsay Santé's existing independence, including its own management and financing arrangements [22] Regulatory and Approval Process - The proposal will require shareholder approval, with a 75% majority needed for the scheme of arrangement to proceed [30] - Regulatory approvals will be based in Australia, with a demerger booklet reviewed by ASIC [16] Tax Implications - Ramsay Health Care will seek class order around demerger relief from the ATO, with details to be outlined in the demerger booklet [41] Engagement with Stakeholders - Ramsay Health Care will engage with all shareholders, including the Paul Ramsay Foundation, to explain the rationale behind the proposal [45] Cost Considerations - While there will be transaction fees and costs associated with preparing the demerger booklet, specific estimates will be provided in future results [48] Additional Insights - The management remains open to discussions regarding any superior alternative outcomes but is committed to progressing with the current proposal [7] - The strategic review has been thorough, involving market testing and engagement with potential interested parties [6][7] This summary encapsulates the key points from the Ramsay Health Care update, focusing on the strategic review, proposed share distribution, and implications for shareholders and the company.

US stocks slid on Friday as investors digested economic data that showed US economic growth cooling in the fourth quarter, while the Fed's favored inflation gauge heated up to end last year. Wall Street also kept an eye out for US-Iran tensions, private credit jitters, and a potential Supreme Court tariff decision. The S&P 500 (^GSPC) moved down roughly 0.3%, while the Dow Jones Industrial Average (^DJI) fell by a steeper 0.4%, coming off the end of a three-day winning streak on Thursday. The Nasdaq Compo ...

Core Viewpoint - A class action lawsuit has been filed against agilon health, inc. for allegedly making false statements and failing to disclose critical information regarding its financial guidance and the impact of strategic actions taken by the company [4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased agilon securities between February 26, 2025, and August 4, 2025, alleging that the company issued misleading guidance for 2025 despite being aware of significant industry challenges [4]. - The lawsuit claims that agilon overstated the positive financial impact from its strategic actions aimed at reducing risk [4]. Group 2: Company Events - On August 4, 2025, agilon announced the resignation of its President and CEO, Steven Sell, which was classified as a termination without cause [5]. - The same day, agilon reported its second-quarter results and acknowledged that industry headwinds were more severe than previously anticipated, leading to the suspension of its full-year 2025 financial guidance [5]. - Following these announcements, agilon's stock price fell by $0.94, or approximately 51.6%, from $1.82 to $0.88 per share [5].

Core Insights - The 2025 Q4 earnings cycle has shown resilience with strong overall growth among S&P 500 companies, particularly highlighted by Cardinal Health (CAH) and Palantir (PLTR) delivering notably strong results [1][9]. Palantir Performance - Palantir reported sales of $1.4 billion, reflecting a 70% year-over-year growth, with U.S. sales reaching $1.1 billion, up 93% year-over-year and 28% sequentially [2][3]. - The company secured over $4.2 billion in total contract value (TCV), marking an increase of more than 130% from the previous year [3]. - Palantir's customer base expanded by 34% compared to the year-ago period [3]. Cardinal Health Performance - Cardinal Health achieved a double-beat relative to consensus expectations, with sales increasing by 18.8% year-over-year and adjusted EPS growing by 36.3% year-over-year [10]. - The growth was broad-based, particularly in Pharmaceuticals and Specialty Solutions, which saw a 19% year-over-year increase and accounts for approximately 90% of total sales [11]. - Following the strong quarterly performance, Cardinal Health raised its FY26 outlook, projecting adjusted EPS in the range of $10.15 - $10.35, indicating a 24.5% year-over-year growth [12].

Core Insights - Pediatrix Medical Group's shares fell over 12% following its earnings report, indicating market disappointment with the results [1] Financial Performance - In Q4, Pediatrix reported revenue of nearly $493.8 million, a decrease of almost 2% year-over-year [2] - Non-GAAP net income fell to $42.5 million ($0.50 per share) from $43.5 million in the previous year [2] - Analysts had expected lower revenue of $486.2 million but higher profitability, with a consensus for non-GAAP net income at $0.54 per share [3] Cost and Profitability Concerns - The company's profitability was negatively impacted by increased bonus payouts to practitioners due to a tightening labor market [3] - Despite challenges, Pediatrix has historically managed to deliver growth and maintain decent profits [5] Future Guidance - Pediatrix provided selective guidance, expecting adjusted EBITDA of $280 million to $300 million for full-year 2026, up from $275.6 million the previous year [4] Investment Sentiment - Given the anticipated tepid growth figures, the company is not viewed as a compelling buy, even after the recent price drop [5] - Pediatrix Medical Group was not included in a list of top stocks recommended by analysts, suggesting a cautious outlook for potential investors [6]

Core Viewpoint - Ramsay Health Care plans to distribute its 52.79% stake in Ramsay Sante to shareholders, effectively separating from the French-listed business [1]. Group 1: Company Actions - Ramsay Health Care will separate from Ramsay Sante by distributing its majority stake to shareholders [1]. - The decision marks a significant strategic shift for Ramsay Health Care, indicating a focus on its core operations outside of the French market [1].

Core Insights - Science Applications International Corp. (SAIC) has launched the Alliance for Advancing Rural Healthcare (AARH) to support the Rural Health Transformation (RHT) Program, a federal initiative aimed at enhancing healthcare systems in rural communities [1][2] - The RHT Program represents a significant federal investment in rural healthcare, emphasizing the need for effective execution to translate funding into improved healthcare access and outcomes [2][3] Company Overview - SAIC is a leading Fortune 500 mission integrator with a focus on technology and innovation, generating annual revenues of approximately $7.5 billion [5] - The AARH includes partnerships with organizations such as Arcadia, Castlight Health, Covista, Mission Mobile Medical, Telemedicine.com, TruBridge, and Walgreens, each contributing unique expertise to address rural healthcare challenges [1][3] Industry Context - The RHT Program is described as a once-in-a-generation opportunity for states to enhance rural healthcare, requiring collaboration and execution beyond mere funding [3] - AARH aims to assist state governments in overcoming challenges related to public sector accountability and healthcare operations, ensuring sustainable, people-centered solutions for rural communities [3] Partner Contributions - Each partner in the AARH brings specialized capabilities: - SAIC integrates AI, data management, and cybersecurity solutions [3] - Arcadia focuses on improving provider performance through data analytics [3] - Castlight Health enhances care navigation and access [3] - Covista addresses workforce needs by educating healthcare professionals [3] - Mission Mobile Medical expands access through mobile healthcare delivery [3] - Telemedicine.com provides telemedicine solutions to improve care access [3] - TruBridge supports rural hospitals with financial sustainability solutions [3] - Walgreens offers essential care in underserved areas through community pharmacies [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - The Class Period for the agilon securities is from February 26, 2025, to August 4, 2025 [1] - Investors who purchased agilon securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 2, 2026 [3] Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding agilon's financial guidance for 2025, which they knew was unattainable due to industry challenges [5] - It is claimed that defendants overstated the positive financial impact from strategic actions taken by agilon to mitigate risks [5] - As a result, the statements made about agilon's business operations and prospects were materially false and misleading, leading to investor damages when the truth was revealed [5] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and success in this area [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Ardent Health, Inc. securities between July 18, 2024, and November 12, 2025, of the March 9, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Ardent Health securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2] - The lead plaintiff must file a motion with the Court by March 9, 2026, to represent other class members in the litigation [2] Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3] Group 3: Case Allegations - The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable, claiming an active monitoring process that was not actually employed [4] - Defendants downplayed increased claim denials by third-party payors and did not write off uncollectible accounts, leading to inflated accounts receivable reporting [4] - Ardent Health's professional liability reserves were insufficient to cover claims, contrary to their public statements about maintaining adequate insurance [4]